Stocktoria
RAPID MICRO BIOSYSTEMS, INC. RPID
RAPID MICRO BIOSYSTEMS, INC. (RPID) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $33.6M at a -140.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RPID | RAPID MICRO BIOSYSTEMS, INC. | 2/9 | — | — | +19.7% |
| EYPT | EyePoint, Inc. | 1/9 | -3.58 | — | -27.5% |
| BNGO | Bionano Genomics, Inc. | 3/9 | — | — | -7.4% |
| SEER | Seer, Inc. | 3/9 | 4.62 | — | +17% |
| PRPO | Precipio, Inc. | 7/9 | -13.13 | — | +28% |
| ASTC | ASTROTECH Corp | 2/9 | — | — | — |
| HBIO | HARVARD BIOSCIENCE INC | 4/9 | -10.45 | — | -8.1% |
About RAPID MICRO BIOSYSTEMS, INC.
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
FAQ
Is RPID financially healthy?
RAPID MICRO BIOSYSTEMS, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does RPID pay a dividend?
No, RAPID MICRO BIOSYSTEMS, INC. does not currently pay a dividend.
How profitable is RPID?
In FY2025, RAPID MICRO BIOSYSTEMS, INC. had a net margin of -140.3% and a return on equity of -141.9%.
What is the analyst price target for RPID?
The average Wall-Street price target for RAPID MICRO BIOSYSTEMS, INC. is $6.67, about 294.5% above the recent price, from 3 analysts.
Is RPID a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RAPID MICRO BIOSYSTEMS, INC.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.